

Special Issue

Vaccines and Therapeutic Approaches in Dermatological Diseases

Message from the Guest Editors

Diseases and deaths can be prevented by vaccines. Vaccines have often been developed to fight bacterial and viral diseases, most recently against COVID-19. In recent years, vaccines against solid tumors and skin cancer have seen increased development. In allergology, vaccines are also successfully used for hyposensitisation against certain allergens. The vaccines modify the immune system by interacting with the antigen, DNA, RNA or allergen and triggering a B- and T-cell response. Vaccinations have also been associated with cutaneous reactions in the past. Thus, "Vaccines and Therapeutic Approaches in Dermatological Diseases" is an important research topic. This Special Issue welcomes all articles, reviews, meta-analyses and diagnostic methods that shed new light on the mechanisms and therapeutic approaches in dermatological diseases. We look forward to receiving contributions that address potential targets of future vaccines in dermatological diseases. Contributions describing cutaneous vaccination reactions and complications are also welcome.

Guest Editors

Prof. Dr. Thilo Gambichler

1. Department of Dermatology, Dortmund Hospital, University Witten/Herdecke, 44137 Dortmund, Germany
2. Department of Dermatology and Phlebology, Christian Hospital Unna, 59423 Unna, Germany

Dr. Nesser Abu Rached

1. International Centre for Hidradenitis Suppurativa/Acne Inversa, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany
2. Skin Cancer Center, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany

Deadline for manuscript submissions

closed (31 December 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/168116

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).